We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Leading Proteomics Company Transitions to Emerald Bio

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

These changes are part of the strategy to address the fact that protein scientists are facing more difficult proteomics targets in larger numbers, problems Emerald Bio has already solved while enabling structural genomics and drug discovery initiatives.

"Our new company name, as well as our personnel changes, reflect Emerald's strengthening position in the protein science industry and our renewed dedication to meeting our customers' growing demands," said Johan Pontin, Chairman of the Board of Beryllium, LLC, which owns Emerald Bio and its sister company, Emerald BioStructures.

"These changes will help Emerald Bio better address the growing demand for high performance and high quality protein science solutions," said George Abe, CEO of Emerald Bio and veteran in the commercialization of biotechnology. "Emerald Bio's protein technology expertise provides high quality reagents, instruments, and consumables -- products that are making key contributions to the growing field of proteomics."

Peter Nollert, Emerald Bio's Chief Technologist and renowned membrane protein scientist commented, "Our strategic vision is to create technology solutions that respond to trends in the growing proteomics field. Emerald Bio's historical leadership in protein crystallography puts us in a strong position to serve all scientists who work in protein science."

George Abe is known for leading companies, and building teams, focused on applying innovation to address critical unmet needs in life sciences. He was most recently CEO of Cambridge Research and Instrumentation (CRi), a provider of multiplexed biomarker imaging solutions. CRi was acquired by Caliper Life Sciences (now Perkin Elmer), where he held the position of Senior Vice President, Tissue Imaging. He has also held senior positions at several high technology organizations, including technology pioneer, BBN. He has also served on the board of directors of several public and private medical device and technology companies. George earned a B.S. degree from Trinity College, a M.S. degree from the University of Connecticut, and is a graduate of the Greater Boston Executive Program at the Sloan School of Management, MIT.

Peter Nollert is a recognized expert in structural and membrane protein science. He earned a PhD in Biochemistry at the University of Tuebingen, and Post-doctorate fellowships at University of Basel, Stanford, and UCSF. Peter holds five U.S. patents, has published more than 30 articles in peer-reviewed journals, and obtained several NIH-funded grants for membrane protein crystallization and imaging technology development.